How many drugs treat Bronchiectasis?

Drug Landscape tracks 10 marketed treatments for Bronchiectasis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Bronchiectasis?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bronchiectasis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bronchiectasis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchiectasis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bronchiectasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Tornalate	BITOLTEROL	Sanofi	bitolterol	Beta-2 adrenergic receptor	1984-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Bupivacaine Hydrochloride And Epinephrine	Epinephrine	Pfizer Inc.	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01
Noradrenaline	Noradrenaline	Tanta University		Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor
Acetylcystein	Acetylcystein	University Hospital, Strasbourg, France		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase
L-cysteine	L-cysteine	Louisiana State University Health Sciences Center Shreveport	Amino acid derivative	Cystine/glutamate transporter
Epinephrin	Epinephrin	United States Naval Medical Center, San Diego		Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor
Acetadote	Acetadote	University of Texas Southwestern Medical Center		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US
2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 2 drugs in Bronchiectasis
Bristol-Myers Squibb · 1 drug in Bronchiectasis
Exela Pharma · 1 drug in Bronchiectasis
Louisiana State University Health Sciences Center Shreveport · 1 drug in Bronchiectasis
Pfizer · 1 drug in Bronchiectasis
Sanofi · 1 drug in Bronchiectasis
Tanta University · 1 drug in Bronchiectasis
United States Naval Medical Center, San Diego · 1 drug in Bronchiectasis
University Hospital, Strasbourg, France · 1 drug in Bronchiectasis
· 1 drug in Bronchiectasis
University of Texas Southwestern Medical Center · 1 drug in Bronchiectasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bronchiectasis:

Cite this brief

Drug Landscape (2026). Bronchiectasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bronchiectasis. Accessed 2026-06-10.

Bronchiectasis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing